Tabernanthalog
Tabernanthalog is a non-selective serotonin receptor modulator and putatively non-psychedelic psychoplastogen of the ibogalog group related to the iboga alkaloid tabernanthine but with a simplified chemical structure. It was developed by David E. Olson and colleagues at the University of California, Davis. The drug is being developed by Delix Therapeutics as a potential pharmaceutical drug for treatment of neuropsychiatric disorders.
Use and effects
There have been informal anecdotal reports of the effects of tabernanthalog. It is said to be psychoactive and mildly hallucinogenic at sufficiently high doses and to have a long duration. Its hallucinogenic effects have been said to be similar to but weaker than those of serotonergic psychedelics. There were also reports of side effects like nausea, dizziness, stomach discomfort, and diarrhea. However, it is unclear whether the reports have always employed actual tabernanthalog.Interactions
Pharmacology
Pharmacodynamics
Tabernanthalog is a non-selective and non-psychedelic serotonin receptor modulator, including acting as an agonist of the serotonin 5-HT1B, 5-HT1F, 5-HT2A, 5-HT2C, and 5-HT6 receptors and as an agonist or antagonist of the serotonin 5-HT2B receptor. It also shows significant binding to the serotonin transporter , the α2A-adrenergic receptor, and monoamine oxidase A. In contrast to iboga alkaloids like ibogaine and noribogaine, tabernanthalog showed negligible interactions with opioid receptors, the NMDA receptor, and certain nicotinic acetylcholine receptors. However, in subsequent research, it weakly inhibited certain nicotinic acetylcholine receptors, as well as, to a much lesser extent, the GABAA receptor. Tabernanthalog was found to be 100-fold less potent at the hERG antitarget compared to ibogaine, and hence is thought to have a much lower potential for cardiotoxicity.Tabernanthalog did not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence appears to be non-hallucinogenic. However, it was found to promote structural neuroplasticity, reduce drug-seeking behavior, and produce antidepressant-like effects. It has also been shown that it reduces motivation for heroin and alcohol in rodents.